Market research and consulting firm Frost & Sullivan said on Tuesday that it has awarded ZAGENO, a procurement orchestration platform for life sciences, its 2026 North America Life Sciences E-Commerce Company of the Year Recognition for helping transform life sciences e-commerce beyond traditional online purchasing into a unified procurement orchestration platform.
By serving as a single entry point into scientific procurement, ZAGENO enables scientists, procurement teams, suppliers, and enterprise systems to operate within one connected workflow, reducing procurement friction while improving governance, visibility, and operational efficiency across research organisations.
"We're honoured to receive this recognition from Frost & Sullivan," commented Florian Wegener, CEO and co-founder of ZAGENO. "As research organisations become more connected and more complex, procurement has evolved far beyond purchasing. Our vision has always been to simplify that complexity by bringing scientists, procurement teams, suppliers, and enterprise systems together through a single procurement orchestration platform. We're proud to see that vision recognised, and even more excited about what's ahead for our customers."
Each year, Frost & Sullivan honours one company with its Company of the Year Recognition for organisations that demonstrate exceptional growth, innovation, and customer value. The selection process includes rigorous research, competitive benchmarking, and in-depth industry analysis.
Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
GSK wins US FDA approval for chronic hepatitis B treatment Hibsago
Summit Therapeutics and ECOG-ACRIN launch Phase II/III trial collaboration for biliary tract cancer
RxMP Therapeutics secures DARPA contract worth up to USD10.7m
TNutra launches NeuraLegend brain health supplements
Health Canada approves AbbVie psoriasis treatment for children
Oracle partners AstraZeneca for AI-enabled healthcare innovation
Eli Lilly and Company reports positive one-year results for Omvoh in paediatric ulcerative colitis
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
GSK reports 61% response rate for investigational lung cancer drug